AKESO(HK:09926) 智通财经网·2025-09-23 05:45Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Kangfang Biotech (09926), which increased by nearly 5% to HKD 137.5, with a trading volume of HKD 1.212 billion [1] - Kangfang Biotech's innovative bispecific antibody drug, Ivosidenib (PD-1/VEGF bispecific), has been selected for a Late-Breaking Abstract presentation at the 2025 European Society for Medical Oncology (ESMO) annual meeting, scheduled for October 17-21 in Berlin [1] - The primary investigator, Professor Lu Shun from Shanghai Chest Hospital, will present the results of the pivotal Phase III clinical study (AK112-306/HARMONi-6) comparing Ivosidenib combined with chemotherapy against Tislelizumab combined with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) at the Presidential Symposium [1] Group 2 - Morgan Stanley's report indicates that the total market capitalization of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, significantly outpacing the Hang Seng Index's 34% rise, reflecting a major shift in market recognition of local pharmaceutical companies' innovation capabilities [1] - The report anticipates that the Federal Reserve's accelerated interest rate cuts will enhance risk appetite, directing funds towards growth sectors such as Chinese biotech [1] - However, Morgan Stanley notes that the performance of individual stocks will still depend on the companies' fundamentals, including commercialization execution and innovation research progress, expressing optimism for companies with short-term catalysts like Kangfang Biotech [1]